Fluidigm Corporation, the inventor of integrated fluidic circuits (IFCs), has appointed Bio-Gene Technology Ltd. as its exclusive distributor for the BioMark™ System for Genetic Analysis in Hong Kong. The BioMark System has significant advantages for real-time PCR, genotyping, gene expression, copy number variation and absolute quantification for sequencing.

Fluidigm Corporation, the inventor of integrated fluidic circuits (IFCs), has appointed Bio-Gene Technology Ltd. as its exclusive distributor for the BioMark™ System for Genetic Analysis in Hong Kong. The BioMark System has significant advantages for real-time PCR, genotyping, gene expression, copy number variation and absolute quantification for sequencing.

Gentel® Biosciences, Inc., a protein microarray life sciences company, announces it has placed its first APiX™ Colorimetric Protein Array Reader at the Centre for Proteomic and Genomic Research (CPGR) in Cape Town, South Africa.

Asuragen, Inc. announced today the launch of Signature® NPM1 Mutations (RUO), a multiplex reverse transcription PCR (RT-PCR) assay that enables the detection of NPM1 mutations. Asuragen’s Signature® NPM1 Mutations is a sensitive molecular assay for the combined detection of mutations A, B and D in exon 12 of the nucleophosmin (NPM1) gene. Asuragen is one of two exclusive licensees to NPM1. The assay is performed on the Luminex® 100™ IS or 200™ System using a liquid bead array method. The liquid bead array format provides comprehensive information in a single well, providing efficiency and cost benefits to the laboratory.

Lumera Corporation (NASDAQ:LMRA), a leader in the field of photonic communications, announced today that on August 14, 2008 it received a letter from The NASDAQ Stock Market indicating that for the last 30 consecutive business days the bid price of its common stock has closed below the minimum $1.00 per share requirement for continued inclusion under Marketplace Rule 4450(a)(5). This notification has no immediate effect on the listing of or the ability to trade Lumera’s common stock on The NASDAQ Global Market.

ModiroTM automates the identification of post-translational modifications (PTMs) of proteins by mass spectrometry to provide more comprehensive information while reducing the time needed for analysis. ModiroTM carries out high throughput analysis of thousands of mass spectrometry profiles in parallel, to iden­tify unknown mass shifts, sequence errors and unspecific enzymatic cleavage of amino acids. In a single step, ModiroTM enables these variances to be clearly visualized and evaluated via an unique interface. The analysis of many spectra in parallel, together with the analysis in­terface, provides a more complete characterization of the protein at a faster rate than previously possible.

Nanogen, Inc. (NASDAQ: NGEN), developer of molecular and rapid in vitro diagnostic products, and The Elitech Group, a private French diagnostics company, announced a definitive agreement to combine the two companies. The combination will create a global provider of products to the molecular, point-of-care, clinical chemistry and microbiology diagnostics markets with expected first year revenues of more than $150 million and positive EBITDA.

Affymetrix Inc. (Nasdaq:AFFX) announced today that researchers around the world have used the Affymetrix Genome-Wide Human SNP Arrays 5.0 and 6.0 to uncover important links between copy number variations (CNVs) and schizophrenia. Researchers from the United States, Europe and Asia published their findings in recent issues of Nature and Nature Genetics.

Gentel® Biosciences, a protein microarray life sciences company, announces it has obtained an exclusive license to novel technology for manufacturing highly-reproducible nitrocellulose protein microarray slides.

Nanogen, Inc. (Nasdaq:NGEN), developer of in vitro diagnostic products, today reported its unaudited financial results for the quarter ended June 30, 2008.

Nanogen, Inc. (Nasdaq:NGEN), developer of innovative, high-quality diagnostic products, will host a conference call on Thursday, August 14, 2008 at 4:30 p.m. Eastern (1:30 p.m. Pacific) to discuss 2008 second quarter results. The financial results press release will be issued at market open on August 14, 2008. Interested investors and others may participate in the conference call by dialing 866.362.5158 for US/Canada participants and 617.597.5397 for international participants. The conference ID will be 66510183.

Illumina, Inc. (NASDAQ:ILMN) today announced that the underwriter of the public offering of the Company’s common stock fully exercised its option to purchase up to 525,000 additional shares.

Source: Illumina

Agilent Technologies Inc. (NYSE: A) today announced that IMGM Laboratories GmbH has achieved Certified Service Provider status for the Agilent microarray platform.

Sense Proteomic Ltd today announced that it has expanded its biomarker IP portfolio through filing a patent covering a novel panel of biomarkers for the early diagnosis of Systemic Lupus Erythematosus (Lupus).

Luminex Corporation (NASDAQ:LMNX) today announced that management will present at the Canaccord Adams 28th Annual Global Growth Conference to be held August 12-14, 2008, in Boston.

Soruce: Luminex